Updated:
Sunstone Life Science Ventures
Life science venture investor focused on European drug development. | Sunstone Life Science Ventures’ is a European, early-stage investor based in Copenhagen.
Sunstone Life Science Ventures
Life science venture investor focused on European drug development. | Sunstone Life Science Ventures’ is a European, early-stage investor based in Copenhagen. We invest in drug development opportunities across the European Life Science sector, and prefer to make our initial investment in companies raising Series A/B rounds based on solid in-vivo preclinical data and a well understood mechanism of action that fits well into the pathology.
General information
Firm type
Venture Capital
Year founded
2007
Location
Region
Europe
Country
Denmark
City
Frederiksberg
Corporate office
Nordre Fasanvej 215, 2000 Frederiksberg, Denmark
Principals
Sten Verland
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Sunstone Life Science Ventures?
Sten Verland serves as Managing Partner and co-founded the firm, overseeing investment strategy for the series of dedicated life science funds. The team is built from professionals with scientific and industry experience, but the firm’s website identifies Verland as the lead partner for the overall operation.
Does Sunstone Life Science Ventures participate in fund commitments or only direct deals?
The firm invests directly in early-stage life science companies through its own fund structures. Its website does not indicate a fund-of-funds program — capital is deployed as direct equity into portfolio companies developing human therapeutics.
What investment stages does Sunstone Life Science Ventures typically target?
Sunstone targets early-stage companies, spanning from pre-clinical drug candidates through clinical Phase 1, Phase 2, and Phase 3 studies. The strategy is built to support novel therapeutics from the lab through regulatory milestones and toward market approval or exit.
Which sectors does Sunstone Life Science Ventures explicitly avoid?
Sunstone focuses exclusively on therapeutics for humans and does not signal any activity in medical devices, diagnostics, digital health, or health services. The firm’s stated mandate is concentrated on novel human drug development, making it a pure therapeutics investor within the life sciences landscape.
How is Sunstone Life Science Ventures related to the European Union’s investment initiatives?
Sunstone is supported by InnovFin Equity, with financial backing from the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments. This EU relationship provides a layer of public-policy-aligned capital alongside the firm’s private venture funds, helping bridge long R&D timelines with financial returns.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: